Compare
ADMA Biologics vs Amgen (ADMA vs AMGN)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year ADMA Biologics (ADMA) returned -17.2% and Amgen (AMGN) +43.9%; so far this year the figures are -30.2% and +40.7%.
Amgen is the larger company by market value, about 88.3 times the size of ADMA Biologics.
On trailing earnings, ADMA trades at 16.5 times and AMGN at 26.7 times.
Revenue grew +6.3% at ADMA and +8.2% at AMGN over the last year.
ADMA pays no dividend. AMGN yields 2.16%.
Data as of the latest close. Not investment advice.
Relative performance
| ADMA | AMGN | |
|---|---|---|
| Price | $12.73 | $460.42 |
| 1-day | -3.63% | +0.03% |
| YTD | -30.21% | +40.67% |
| 1 year | -17.18% | +43.94% |
| 3 years | +261.65% | +76.51% |
| Market cap | $2.8B | $249.1B |
| P/E | 16.5 | 26.7 |
| P/S | 5.44 | 6.40 |
| P/B | 6.44 | 17.35 |
| Revenue growth | +6.30% | +8.20% |
| EPS growth | -10.50% | +33.30% |
| Gross margin % | 68.5 | 70.9 |
| Net margin % | 35.1 | 24.1 |
| ROE % | 41.6 | 65.4 |
| Debt / equity | 0.45 | 3.76 |
| FCF yield % | 4.7 | 3.8 |
| Dividend yield % | — | 2.16 |
| Beta | 0.07 | 0.50 |
| RSI (14) | 65.8 | 60.5 |
| Technical rating |